* EBITA margin -90bp y-o-y driven by well-flagged UK logistics.
For Q2, NAV/share increased by 2% q/q and VNV noted a solid performance across its largest holdings.
The report reinforced our positive view on Xvivo's underlying sales development, with heart sales cl...
Although we will likely lower our SEK117 base case, we view the 25% share price drop to SEK31.
Ahead of Atria's Q2 report, we make only minor estimate revisions and derive a DCF- and multiples-ba...
Redeye considers Guldbrev's Q2 report to be fair, posting growth of 25% y/y supported by positive cu...
In July 2025, Endocrine Society delivered the most consequential catalyst for Pentixapharm's late- s...
Yesterday, Semperit raised its full year earnings forecast as the preliminary Q2 26 EBITDA exceeded ...
Enea's Q2 came in line: net sales +1% and adj. EBITDA +3% vs Redeye's estimate, with full-year guida...
Nelly Group's Q2 report was soft, with net sales of SEK 346m, down -4.
Redeye provides its first take on Camurus’ Q2 report 2026, published this morning.
* Net sales SEK 592m, 0% vs ABGSCe, -1% vs Factset cons.
L&T announced a profit warning for FY 2026 and pre-released H1 numbers, reflecting continued high di...
Redeye comments on Hacksaw ahead of Q2-results (due 21 July) where we expect another quarter with so...
Redeye retains its positive view of Vitec following a solid Q2 report, showing underlying sales roug...
We believe Q2 was good news for the base business given that 1) BD revenues grew strongly and were a...
Duni reported weaker numbers than our estimates and we expect disruptions to continue into next quar...
Redeye is positive about Paxman’s regulatory clearance in the EU and UK for its CIPN device.
VNV reported a Q2 NAV per share of SEK 35, up 2% q/q in SEK terms.
Redeye comments on Lime’s Q2 report, beating on sales and EBITA thanks to strong Expert Services whi...